{"Clinical Trial ID": "NCT00305448", "Intervention": ["INTERVENTION 1:", "-Fulvestant 250 mg", "-Fulvestant 250 mg", "INTERVENTION 2:", "- Fulvestant 250 mg + loading dose", "- Fulvestant 250 mg + loading dose"], "Eligibility": ["Incorporation criteria:", "Breast cancer continued to grow after receiving hormonal anti-estrogen therapy such as tamoxifen or an aromatase inhibitor.", "- Requires hormonal treatment", "Menopausal women defined as a woman who has ceased to have menstruation", "- Exclusion criteria:", "Treatment with more than one previous anticancer systemic regimen other than endocrine treatment for advanced breast cancer", "Treatment with more than one previous endocrine regimen for advanced breast cancer", "\u2022 An existing disease, disease or serious condition that will prevent participation or compliance with study procedures"], "Results": ["Performance measures:", "Objective response rate (ORR)", "An objective response (OR) is defined as a patient with the best overall complete (CR) or partial (PR) response. A patient has the best overall response of CR if she has had an overall response of CR or PR during a visit and meets the criteria for confirmation by RECIST. ROR is defined as the percentage of patients with an objective response.", "Each patient with a measurable disease at baseline was evaluated for OR from the sequence of solid tumour response assessment criteria (REST) to the data limit.", "Time frame: database and every 12 weeks (+/- 2 weeks) from randomization data to data threshold (March 19, 2008)", "Results 1:", "Title of arm/group: Fulvestant 250 mg", "Description of the arm/group: Fulvestant 250 mg", "Total number of participants analysed: 45", "Type of measurement: Number", "Unit of measure: percentage of participants 11.1", "Results 2:", "Title of arm/group: Fulvestant 250 mg + loading dose", "Description of the arm/group: Fulvestant 250 mg + loading dose", "Total number of participants analysed: 51", "Type of measurement: Number", "Unit of measure: percentage of participants 17.6"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/45 (4.44 per cent)", "Congestive heart failure 0/45 (0.00 %)", "Differential value 0/45 (0.00 %)", "- Herpes Zoster 1/45 (2.22%)", "Back pain 0/45 (0.00 %)", "Cancer of Fallopian tubes 0/45 (0.00 %)", "Fibroma 0/45 (0.00 %)", "1/45 (2.22%)", "- Dizzying sensations 0/45 (0.00 %)", "Optimal neutral 0/45 (0.00 %)", "Adverse Events 2:", "Total: 5/51 (9.80 per cent)", "Congestive heart failure 1/51 (1.96%)", "Differential value 1/51 (1.96%)", "- Herpes Zoster 0/51 (0.00 %)", "Back pain 1/51 (1.96%)", "Cancer of Fallopian tubes 1/51 (1.96%)", "Fibroma 1/51 (1.96%)", "Infarction of the brain stem 0/51 (0.00 %)", "- Dizzying sensations 0/51 (0.00 %)", "Optimal Neurite 1/51 (1.96%)"]}